ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2020
VA National Precision Oncology Program.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Identifying and Addressing Barriers to Live Primary Prostate Cancer Cell Research in Veterans.Cancer research communications · 2026Pooled it
- Utilization of stakeholder engagement to inform the identification of leading indicators for clinical research enrollment performance in a large integrated health care system: The VA clinical research enrollment summit.Contemporary clinical trials communications · 2026Article
- Trends in lung cancer survival: superior outcomes in US Veterans compared with the general population.JNCI cancer spectrum · 2026Article
- Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate.JCO precision oncology · 2026Article
- Clinical impact of UV mutational signatures in Veterans with cancer.The oncologist · 2025Article
- Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate Cancer.JAMA network open · 2025Article
- New Insights into Colorectal Cancer through the Lens of Precision Oncology and Personalized Medicine: Multi-Omics Helps Aging of Predisposed People.Current aging science · 2025Review
- Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans withJTO clinical and research reports · 2024Article
- Neighborhood Deprivation, Race and Ethnicity, and Prostate Cancer Outcomes Across California Health Care Systems.JAMA network open · 2024Article
- Article
- Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans.The oncologist · 2023Article
- The Maine Cancer Genomics Initiative: Implementing a Community Cancer Genomics Program Across an Entire Rural State.JCO precision oncology · 2023Article
- Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program.JCO precision oncology · 2023Article
- Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program.Journal of cancer research and clinical oncology · 2023Article
- Introduction: Precision Oncology Changes the Game for VA Health Care.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe US Department of Veterans Affairs (VA) is the largest integrated health care system in the US. The VA sees about 50,000 new cancer diagnoses each year and provides care for more than 400,000 veterans with cancer. The heterogeneity of molecular testing practice patterns and methods of testing at VA health care facilities and the increasing number and complexity of molecular tests led to the development of national program for precision oncology. OBSERVATIONS: The National Precision Oncology Program (NPOP) provides tumor sequencing and consultative services for the treatment of veterans with cancer. NPOP is used by nearly all VA oncology practices and has now sequenced > 13,000 samples. The initial focus was on advanced-stage nonsquamous non-small cell lung cancer, which has one of the highest number of mutated genes that result in sensitivity to antineoplastic drugs. Recently, testing was expanded to include metastatic prostate cancer and hematologic malignancies with prior approval. The program also offers cell-free DNA (liquid biopsy) and PD-L1 immunohistochemistry analyses.
conclusionsThe VA NPOP is one of the largest clinical DNA sequencing programs in the US with integrated consultation services and health informatics resources to facilitate patient care, clinical trials, and health outcomes research. The clinical services of NPOP provide cutting-edge oncology services to veterans throughout VA without exacerbating disparities and will be a national resource for research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.